SeekingAlpha · Jan 20, 2026
Compass Therapeutics: Exciting Clinical Updates Inbound For 2026
Compass Therapeutics, Inc. is rated a Buy with strong cash position and strong data readout by the end of 1H 2026. Read more on CMPX stock here.
CM
NASDAQ · CMPX
Compass Therapeutics, Inc.
Healthcare · Biotechnology
$0.96
Up+$0.04 (+3.90%)
Updated Oct 6, 2026, 10:56 PM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 745.36M
- P/E ratio
- -11.33
- Dividend yield
- 0.00%
- 52-week range
- $0.83 – $6.88
- Volume
- 15.83M
- Avg. volume
- 1.88M
Price performance · CMPX
CMPX price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
CMPX closed at $0.96 after 20 trading sessions, down 56.53% for the selected period.
- Last close
- $0.96
- Period change
- -56.53%
- Period low
- $0.86
- Period high
- $2.21
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $0.9099 | $0.9999 | $0.89 | $0.9606 | 15.83M |
| Oct 2, 2026 | $0.9401 | $0.9798 | $0.8294 | $0.8567 | 20.75M |
| Oct 1, 2026 | $1.03 | $1.055 | $0.9009 | $0.9011 | 10.07M |
| Sep 30, 2026 | $1.10 | $1.10 | $1.02 | $1.04 | 5.66M |
| Sep 29, 2026 | $1.125 | $1.15 | $1.09 | $1.10 | 3.5M |
| Sep 28, 2026 | $1.15 | $1.15 | $1.10 | $1.11 | 3.7M |
| Sep 25, 2026 | $1.17 | $1.195 | $1.12 | $1.13 | 3.53M |
| Sep 24, 2026 | $1.17 | $1.17 | $1.10 | $1.135 | 4.54M |
| Sep 23, 2026 | $1.22 | $1.23 | $1.1301 | $1.17 | 7.69M |
| Sep 22, 2026 | $1.25 | $1.44 | $1.15 | $1.24 | 27.2M |
| Sep 21, 2026 | $1.88 | $1.88 | $1.80 | $1.82 | 2.99M |
| Sep 18, 2026 | $1.86 | $1.90 | $1.81 | $1.90 | 8.21M |
| Sep 17, 2026 | $1.88 | $1.94 | $1.84 | $1.85 | 2.52M |
| Sep 16, 2026 | $1.87 | $1.895 | $1.80 | $1.83 | 2.24M |
| Sep 15, 2026 | $1.98 | $1.98 | $1.85 | $1.85 | 2.44M |
| Sep 14, 2026 | $2.025 | $2.04 | $1.96 | $1.96 | 2.28M |
| Sep 11, 2026 | $2.08 | $2.09 | $1.955 | $2.00 | 4.83M |
| Sep 10, 2026 | $2.17 | $2.17 | $2.04 | $2.05 | 2.54M |
| Sep 9, 2026 | $2.22 | $2.2492 | $2.17 | $2.18 | 2.61M |
| Sep 8, 2026 | $2.32 | $2.325 | $2.20 | $2.21 | 2.43M |
Latest CMPX news
The latest Smart Investors Daily articles mentioning CMPX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
CMPX research
Overview
Company profile and research snapshot.
Company profile
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $10.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2026 | Craig-Hallum | Buy | — |
| Sep 23, 2026 | Citizens | Market Outperform | — |
| Sep 23, 2026 | Guggenheim | Buy | — |
| Sep 23, 2026 | Wedbush | Neutral | — |
| Sep 23, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Jan 14, 2026
Compass Therapeutics, Inc. (CMPX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Compass Therapeutics, Inc. (CMPX) 44th Annual J.P.
zacks.com · Dec 8, 2025
Here's Why Compass Therapeutics, Inc. (CMPX) is a Great Momentum Stock to Buy
Does Compass Therapeutics, Inc. (CMPX) have what it takes to be a top stock pick for momentum investors? Let's find out.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
